Psoriasis

Through collaboration with Nimbus Therapeutics and Schrodinger, zasocitinib’s AI-driven design maximizes its fit within the targeted enzyme.

Mona Shahriari, MD, FAAD, shared insights into prevalence, clinical presentations, increasing research diversity, and advocating for representation.

Researchers presented interim 3-year results from the European SERENA study.

Christopher Bunick, MD, PhD, shared insights into zasocitinib’s presented data and ongoing clinical trials.

The FDA has set a PDUFA target action date of May 22, 2025.

Zelma Chiesa Fuxench, MD, MSCE, FAAD, and Mona Shahriari, MD, FAAD, discuss the lack of research into psoriasis in skin of color, the absence of diversity in clinical trial populations, and where dermatology as a discipline can go from here.

Dermavant’s sNDA for tapinarof cream 1% for AD is still under review with the FDA.

Hawkes highlights groundbreaking therapies for psoriasis, including new oral medications and IL-23 inhibitors.

At Maui Derm NP+PA Fall 2024, Melodie Young, MSN, ANP-c, reviews new treatment options for pediatric patients with psoriasis and details the difference in disease manifestation between adults and children.

Armstrong shared insights on the recently released NPF psoriasis health indicator report including pearls on national health data and unmet needs in public health campaigns.

Researchers authored a manuscript detailing considerations for GPP diagnosis, definitions, and management.

The trial showcased the continued efficacy of apremilast, with 2-year data on the forefront.

The study reported that UST leads in dose escalation frequency, but also had lower discontinuation rates when compared to ADA and ETN.

Dermatology Times spoke with Leah Howard, JD, of the NPF, and Trisha, the mother of a young girl with psoriasis, to discuss Otezla's implications in the therapeutic landscape.

The oral TYK2 inhibitor demonstrated biologic-level efficacy.

Throughout the month of August, Dermatology Times covered psoriasis news related to Alumis Inc’s phase 3 trial of ESK-001 for plaque psoriasis, AbbVie’s Science of Skin event, and more.

Rates of infection did not correlate with disease severity, however.

A recent study found prefilled pens with concealed needles showed promise in reducing injection-related anxiety and improving patient adherence.

The National Psoriasis Foundation's new report provides an overview of the health impacts of psoriasis, revealing significant issues in care and outcomes.

The availability is notable as it introduces the first oral treatment option for young psoriasis patients.

Patients showed significant improvements in skin severity, quality of life, blood pressure, and cardiovascular health, with enhanced psychological well-being.

Researchers suggested that itch control is key in reducing disease burden and improving life quality for patients with psoriasis and atopic dermatitis.

Brenda Kong-Tunac, a patient with PsO, PsA, and skin of color, shares her experiences.

Kindred spoke with Dermatology Times to discuss AbbVie's recent Science of Skin event and improving access to equitable dermatological care.

Researchers linked higher exposure to natural environments and green spaces with an increased risk of developing psoriasis.

Increased COPD prevalence in patients with psoriasis likely reflects smoking correlation, according to researchers.

Psoriasis specialists evaluate strategies for integrating emerging therapies into existing treatment protocols and conclude by addressing persistent gaps in current psoriasis management approaches.

Key opinion leaders examine safety concerns and adverse event trends in psoriasis treatments, discussing how these factors influence decisions to discontinue therapy and transition patients to alternative interventions.

Both 8-week and 16-week dosing intervals of guselkumab achieved similar clinical outcomes and patient-reported responses in the GUIDE trial.

Alumis' Martin Babler shared insights into the program for the TYK2 inhibitor and the company's next steps for its development.